Disutilities Associated with Intravenous Iron Infusions: Results from a Time Trade-off Survey and Diminishing Marginal Utility Model for Treatment Attributes in China

References

• Cappellini MD, Musallam KM, Taher AT. Iron deficiency anaemia revisited. J Intern Med. 2020;287(2):153–170. doi:10.1111/joim.13004
   PubMed Web of Science ®Google Scholar
• Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021;397(10270):233–248. doi:10.1016/S0140-6736(20)32594-0
   PubMed Web of Science ®Google Scholar
• Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832–1843. doi:10.1056/NEJMra1401038
   PubMed Web of Science ®Google Scholar
• Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet. 2016;387(10021):907–916. doi:10.1016/S0140-6736(15)60865-0
   PubMed Web of Science ®Google Scholar
• Stugiewicz M, Tkaczyszyn M, Kasztura M, Banasiak W, Ponikowski P, Jankowska EA. The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications. Eur J Heart Fail. 2016;18(7):762–773. doi:10.1002/ejhf.467
   PubMed Web of Science ®Google Scholar
• Strauss WE, Auerbach M. Health-related quality of life in patients with iron deficiency anemia: impact of treatment with intravenous iron. Patient Relat Outcome Meas. 2018;9:285–298. doi:10.2147/PROM.S169653
   PubMed Web of Science ®Google Scholar
• Shen Y, Wang J, Yuan J, et al. Anemia among Chinese patients with chronic kidney disease and its association with quality of life - results from the Chinese cohort study of chronic kidney disease (C-STRIDE). BMC Nephrol. 2021;22(1):64. doi:10.1186/s12882-021-02247-8
   PubMed Web of Science ®Google Scholar
• van Haalen H, Jackson J, Spinowitz B, Milligan G, Moon R. Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data. BMC Nephrol. 2020;21(1):88. doi:10.1186/s12882-020-01746-4
   PubMed Web of Science ®Google Scholar
• DeLoughery TG. Safety of oral and intravenous iron. Acta Haematol. 2019;142(1):8–12. doi:10.1159/000496966
   PubMed Web of Science ®Google Scholar
• Numan S, Kaluza K. Systematic review of guidelines for the diagnosis and treatment of iron deficiency anemia using intravenous iron across multiple indications. Curr Med Res Opin. 2020;36(11):1769–1782. doi:10.1080/03007995.2020.1824898
   PubMed Web of Science ®Google Scholar
• Koch TA, Myers J, Goodnough LT. Intravenous iron therapy in patients with iron deficiency anemia: dosing considerations. Anemia. 2015;2015:763576. doi:10.1155/2015/763576
   PubMed Web of Science ®Google Scholar
• Stoffel NU, von Siebenthal HK, Moretti D, Zimmermann MB. Oral iron supplementation in iron-deficient women: how much and how often? Mol Aspects Med. 2020;75:100865. doi:10.1016/j.mam.2020.100865
   PubMed Web of Science ®Google Scholar
• Datapharm Ltd. Monofer 100mg/mL solution for injection/infusion: summary of product characteristics (SmPC). emc; 2020. Available from: https://www.medicines.org.uk/emc/product/5676/smpc. Accessed February 5, 2022.
   Google Scholar
• Datapharm Ltd. Venofer (iron sucrose) 20 mg iron/mL, solution for injection or concentrate for solution for infusion: summary of product characteristics (SmPC). emc; 2021. Available from: https://www.medicines.org.uk/emc/product/5911. Accessed February 25, 2022.
   Google Scholar
• Datapharm Ltd. Ferinject (ferric carboxymaltose): summary of product characteristics (SmPC). emc; 2022. Available from: https://www.medicines.org.uk/emc/product/5910/smpc. Accessed February 25, 2022.
   Google Scholar
• Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015;90(1):12–23. doi:10.1016/j.mayocp.2014.10.007
   PubMed Web of Science ®Google Scholar
• Blumenstein I, Shanbhag S, Langguth P, Kalra PA, Zoller H, Lim W. Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular safety. Expert Opin Drug Saf. 2021;20(7):757–769. doi:10.1080/14740338.2021.1912010
   PubMed Web of Science ®Google Scholar
• Wolf M, Rubin J, Achebe M, et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. JAMA. 2020;323(5):432–443. doi:10.1001/jama.2019.22450
   PubMed Web of Science ®Google Scholar
• Auerbach M, Henry D, DeLoughery TG. Intravenous ferric derisomaltose for the treatment of iron deficiency anemia. Am J Hematol. 2021;96(6):727–734. doi:10.1002/ajh.26124
   PubMed Web of Science ®Google Scholar
• Kalra PA, Bhandari S, Spyridon M, et al. NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease. BMC Nephrol. 2020;21(1):539. doi:10.1186/s12882-020-02180-2
   PubMed Web of Science ®Google Scholar
• Brennan VK, Dixon S. Incorporating process utility into quality adjusted life years: a systematic review of empirical studies. PharmacoEconomics. 2013;31(8):677–691. doi:10.1007/s40273-013-0066-1
   PubMed Web of Science ®Google Scholar
• Higgins A, Barnett J, Meads C, Singh J, Longworth L. Does convenience matter in health care delivery? A systematic review of convenience-based aspects of process utility. Value Health. 2014;17(8):877–887. doi:10.1016/j.jval.2014.08.2670
   PubMed Web of Science ®Google Scholar
• Mooney G. Beyond health outcomes: the benefits of health care. Health Care Anal. 1998;6(2):99–105. doi:10.1007/BF02678115
   PubMed Web of Science ®Google Scholar
• NICE. Guide to the methods of technology appraisal 2013: process and Methods [PMG9]. London and Manchester: National Institute for Health and Care Excellence; 2013. Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781. Accessed December 5, 2022.
   Google Scholar
• Bien DR, Danner M, Vennedey V, Civello D, Evers SM, Hiligsmann M. Patients’ preferences for outcome, process and cost attributes in cancer treatment: a systematic review of discrete choice experiments. Patient. 2017;10(5):553–565. doi:10.1007/s40271-017-0235-y
   PubMedGoogle Scholar
• Stewart KD, Johnston JA, Matza LS, et al. Preference for pharmaceutical formulation and treatment process attributes. Patient Prefer Adherence. 2016;10:1385–1399. doi:10.2147/PPA.S101821
   PubMed Web of Science ®Google Scholar
• Matza LS, Cutts KN, Stewart KD, Norrbacka K, García-Pérez LE, Boye KS. Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes. Qual Life Res. 2021;30(7):2033–2043. doi:10.1007/s11136-021-02808-2
   PubMed Web of Science ®Google Scholar
• Heckman BW, Mathew AR, Carpenter MJ. Treatment burden and treatment fatigue as barriers to health. Curr Opin Psychol. 2015;5:31–36. doi:10.1016/j.copsyc.2015.03.004
   PubMed Web of Science ®Google Scholar
• Datapharm Ltd. Monofer 100mg/mL solution for injection/infusion: patient information leaflet (PIL). emc; 2021. Available from: https://www.medicines.org.uk/emc/product/5676/pil. Accessed February 25, 2022.
   Google Scholar
• Datapharm Ltd. Ferinject (ferric carboxymaltose): patient information leaflet (PIL). emc; 2022. Available from: https://www.medicines.org.uk/emc/product/5910/pil. Accessed February 25, 2022.
   Google Scholar
• Datapharm Ltd. Venofer (iron sucrose) 20 mg iron/mL, solution for injection or concentrate for solution for infusion: patient information leaflet (PIL). emc; 2020. Available from: https://www.medicines.org.uk/emc/product/5911/pil. Accessed February 25, 2022.
   Google Scholar
• Market Research Society. Code of conduct: October 2019. London, UK: Market Research Society; 2019. Available from: https://www.mrs.org.uk/pdf/MRS-Code-of-Conduct-2019.pdf. Accessed September 6, 2021.
   Google Scholar
• ESOMAR, Global Research Business Network (GRBN). ESOMAR/GRBN online research guideline. Amsterdam: ESOMAR and Global Research Business Network (GRBN); 2015. Available from: https://www.esomar.org/uploads/public/knowledge-and-standards/codes-and-guidelines/ESOMAR-GRBN-Online-Research-Guideline-October-2015.pdf. Accessed September 6, 2021.
   Google Scholar
• National Health and Family Planning Commission. 涉及人的生物医学研究伦理审查办法 [Measures for ethical review of biomedical research involving humans]. Chinese; 2016. Available from: http://www.nhc.gov.cn/fzs/s3576/201610/84b33b81d8e747eaaf048f68b174f829.shtml. Accessed March 30, 2022.
   Google Scholar
• Yang Z, Busschbach J, Timman R, Janssen MF, Luo N. Logical inconsistencies in time trade-off valuation of EQ-5D-5L health states: whose fault is it? PLoS One. 2017;12(9):e0184883. doi:10.1371/journal.pone.0184883
   PubMed Web of Science ®Google Scholar
• Attema AE, Krol M, van Exel J, Brouwer WBF. New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year. Eur J Health Econ. 2018;19(2):277–291. doi:10.1007/s10198-017-0883-9
   PubMed Web of Science ®Google Scholar
• Welch BL. The generalisation of student’s problems when several different population variances are involved. Biometrika. 1947;34(1–2):28–35. doi:10.1093/biomet/34.1-2.28
   PubMed Web of Science ®Google Scholar
• Boye KS, Matza LS, Stewart KD, et al. Health state utilities associated with weight loss in type 2 diabetes and obesity. J Med Econ. 2022;25(1):14–25. doi:10.1080/13696998.2021.2002062
   PubMed Web of Science ®Google Scholar
• Lauridsen JT, Lønborg J, Gundgaard J, Jensen HH. Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries. Qual Life Res. 2014;23(9):2645–2650. doi:10.1007/s11136-014-0712-x
   PubMed Web of Science ®Google Scholar
• Smith G. Modeling (optional). In: Essential Statistics, Regression, and Econometrics. 2nd ed. Amsterdam: Academic Press; 2015:339–367.
   Google Scholar
• R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2021. Available from: https://www.R-project.org/. Accessed October 13, 2021.
   Google Scholar
• Wickham H, Averick M, Bryan J, et al. Welcome to the tidyverse. J Open Source Softw. 2019;4(43):1686. doi:10.21105/joss.01686
   Google Scholar
• Boerma T, Hosseinpoor AR, Verdes E, Chatterji S. A global assessment of the gender gap in self-reported health with survey data from 59 countries. BMC Public Health. 2016;16(1):675. doi:10.1186/s12889-016-3352-y
   PubMedGoogle Scholar
• Cherepanov D, Palta M, Fryback DG, Robert SA. Gender differences in health-related quality-of-life are partly explained by sociodemographic and socioeconomic variation between adult men and women in the US: evidence from four US nationally representative data sets. Qual Life Res. 2010;19(8):1115–1124. doi:10.1007/s11136-010-9673-x
   PubMed Web of Science ®Google Scholar
• Tegenge MA, Belov A, Moncur M, Forshee R, Irony T. Comparing clotting factors attributes across different methods of preference elicitation in haemophilia patients. Haemophilia. 2020;26(5):817–825. doi:10.1111/hae.14119
   PubMed Web of Science ®Google Scholar
• Boye KS, Matza LS, Walter KN, Van Brunt K, Palsgrove AC, Tynan A. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ. 2011;12(3):219–230. doi:10.1007/s10198-010-0224-8
   PubMed Web of Science ®Google Scholar
• Igarashi A, Bekker Hansen B, Langer J, et al. Preference for oral and injectable GLP-1 RA therapy profiles in Japanese patients with type 2 diabetes: a discrete choice experiment. Adv Ther. 2021;38(1):721–738. doi:10.1007/s12325-020-01561-1
   PubMed Web of Science ®Google Scholar
• Mansfield C, Ndife B, Chen J, Gallaher K, Ghate S. Patient preferences for treatment of metastatic melanoma. Future Oncol. 2019;15(11):1255–1268. doi:10.2217/fon-2018-0871
   PubMed Web of Science ®Google Scholar
• Matza LS, Boye KS, Stewart KD, Davies EW, Paczkowski R. Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. BMC Health Serv Res. 2017;17(1):774. doi:10.1186/s12913-017-2648-7
   PubMed Web of Science ®Google Scholar
• Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68(6):2846–2856. doi:10.1111/j.1523-1755.2005.00758.x
   PubMed Web of Science ®Google Scholar
• Moran K, Null K, Huang Z, Lissoos T, Kane S. Retrospective claims analysis indirectly comparing medication adherence and persistence between intravenous biologics and oral small-molecule therapies in inflammatory bowel diseases. Adv Ther. 2019;36(9):2260–2272. doi:10.1007/s12325-019-01037-x
   PubMed Web of Science ®Google Scholar
• Ziller V, Kostev K, Kyvernitakis I, Boeckhoff J, Hadji P. Persistence and compliance of medications used in the treatment of osteoporosis--analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther. 2012;50(5):315–322. doi:10.5414/cp201632
   PubMed Web of Science ®Google Scholar
• da Costa DiBonaventura M, Copher R, Basurto E, Faria C, Lorenzo R. Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer. Am Health Drug Benefits. 2014;7(7):386–396.
   PubMedGoogle Scholar
• Galloway R, McGuire J. Determinants of compliance with iron supplementation: supplies, side effects, or psychology? Soc Sci Med. 1994;39(3):381–390. doi:10.1016/0277-9536(94)90135-X
   PubMed Web of Science ®Google Scholar
• Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19(4):279–284. doi:10.1046/j.1464-5491.2002.00689.x
   PubMed Web of Science ®Google Scholar
• Buysman EK, Liu F, Hammer M, Langer J. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study. Adv Ther. 2015;32(4):341–355. doi:10.1007/s12325-015-0199-z
   PubMed Web of Science ®Google Scholar
• Horii T, Momo K, Yasu T, Kabeya Y, Atsuda K. Determination of factors affecting medication adherence in type 2 diabetes mellitus patients using a nationwide claim-based database in Japan. PLoS One. 2019;14(10):e0223431. doi:10.1371/journal.pone.0223431
   PubMed Web of Science ®Google Scholar
• Matza LS, Stewart KD, Lloyd AJ, Rowen D, Brazier JE. Vignette-based utilities: usefulness, limitations, and methodological recommendations. Value Health. 2021;24(6):812–821. doi:10.1016/j.jval.2020.12.017
   PubMed Web of Science ®Google Scholar
• Arnesen TM, Norheim OF. Quantifying quality of life for economic analysis: time out for time trade off. Med Humanit. 2003;29(2):81–86. doi:10.1136/mh.29.2.81
   PubMedGoogle Scholar
• Lugnér AK, Krabbe PFM. An overview of the time trade-off method: concept, foundation, and the evaluation of distorting factors in putting a value on health. Expert Rev Pharmacoecon Outcomes Res. 2020;20(4):331–342. doi:10.1080/14737167.2020.1779062
   PubMed Web of Science ®Google Scholar
• Attema AE, Edelaar-Peeters Y, Versteegh MM, Stolk EA. Time trade-off: one methodology, different methods. Eur J Health Econ. 2013;14(Suppl 1):53–64. doi:10.1007/s10198-013-0508-x
   PubMed Web of Science ®Google Scholar
• Stolk E, Ludwig K, Rand K, Hout B, Ramos-Goñi JM. Overview, update, and lessons learned from the international EQ-5D-5L valuation work: version 2 of the EQ-5D-5L valuation protocol. Value Health. 2019;22(1):23–30. doi:10.1016/j.jval.2018.05.010
   PubMed Web of Science ®Google Scholar
• Heerwegh D, Loosveldt G. Face-to-face versus web surveying in a high-internet-coverage population: differences in response quality. Public Opin Q. 2008;72(5):836–846. doi:10.1093/poq/nfn045
   Web of Science ®Google Scholar
• Boye KS, Matza LS, Stewart KD, et al. Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy. J Med Econ. 2019;22(8):806–813. doi:10.1080/13696998.2019.1609482
   PubMed Web of Science ®Google Scholar
• Matza LS, Cong Z, Chung K, et al. Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases. Patient Prefer Adherence. 2013;7:855–865. doi:10.2147/PPA.S44947
   PubMed Web of Science ®Google Scholar
• Matza LS, Paramore LC, Stewart KD, Karn H, Jobanputra M, Dietz AC. Health state utilities associated with treatment for transfusion-dependent β-thalassemia. Eur J Health Econ. 2020;21(3):397–407. doi:10.1007/s10198-019-01136-0
   PubMed Web of Science ®Google Scholar
• Jizhe N. Main data of the seventh national population census: news release. Beijing: National Bureau of Statistics of China; 2021. Available from: http://www.stats.gov.cn/english/PressRelease/202105/t20210510_1817185.html. Accessed March 30, 2022.
   Google Scholar
• Hu S, Liu L, Pollock RF, Pöhlmann J, Wu D, Zhang Y. Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose. J Med Econ. 2022;25(1):561–570. doi:10.1080/13696998.2022.2065092
   PubMed Web of Science ®Google Scholar
• Pollock RF, Biggar P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Rev Hematol. 2020;13(2):187–195. doi:10.1080/17474086.2020.1709437
   PubMed Web of Science ®Google Scholar
• Bellos I, Frountzas M, Pergialiotis V. Comparative risk of hypophosphatemia following the administration of intravenous iron formulations: a network meta-analysis. Transfus Med Rev. 2020;34(3):188–194. doi:10.1016/j.tmrv.2020.07.002
   PubMed Web of Science ®Google Scholar
• Auerbach M, Macdougall I. The available intravenous iron formulations: history, efficacy, and toxicology. Hemodial Int. 2017;21(S1):S83–S92. doi:10.1111/hdi.12560
   PubMedGoogle Scholar
• Pollock RF, Muduma G. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom. J Med Econ. 2020;23(7):751–759. doi:10.1080/13696998.2020.1745535
   PubMed Web of Science ®Google Scholar